Close menu




November 1st, 2024 | 07:00 CET

Takeover fever and buy recommendation! Evotec, Nel ASA, Barrick Gold, Desert Gold

  • Mining
  • Gold
  • Biotechnology
  • Pharma
  • renewableenergies
Photo credits: pixabay.com

A hot takeover candidate in the gold sector is Desert Gold. Gold production in West Africa is expected to start in 2025. It is quite possible that one of the major gold companies will make a move by then. After the disappointing quarterly figures from Barrick Gold and Newmont calls for takeovers are growing louder. Analysts see significant upside potential. In the biotech sector, Evotec is repeatedly being discussed as a takeover candidate. The core business is considered extremely attractive, and the new CEO is expected to eliminate all the legacy issues this year. Next week will be exciting! And then there is Nel. Operationally, things are not going well for the former hydrogen star. Can the collaboration with a potential buyer turn things around?

time to read: 3 minutes | Author: Fabian Lorenz
ISIN: DESERT GOLD VENTURES | CA25039N4084 , EVOTEC SE INH O.N. | DE0005664809 , NEL ASA NK-_20 | NO0010081235 , BARRICK GOLD CORP. | CA0679011084

Table of contents:


    Desert Gold: Buy recommendation and increasing takeover speculation

    Desert Gold appears to be an ideal takeover candidate. Gold production is scheduled to start next year on the 440 km2 site in West Africa. The project is strategically located between well-known gold companies such as B2Gold, Barrick Gold, and Endeavour Mining. Calls for acquisitions are growing louder, particularly at Barrick Gold and Newmont. Despite record-high gold prices, the two industry heavyweights have disappointed in the last quarter. A project on the verge of production – as with Desert Gold – would be an excellent fit.

    Desert Gold currently has a gold resource of 1.1 million ounces. At the current share price, this is valued at just over USD 10 per ounce. The gold deposit is likely to be significantly larger since only 5 of 27 gold zones have been analyzed so far. While the PEA is currently being prepared, the desert management has provided key data for production. According to this, gold production is expected to start in the second half of 2025 in two open-pit mines with a total of approximately 200,000 ounces. Due to the efficient mining by heap leaching, production costs per ounce of gold are expected to be in the range of USD 800 to USD 1,300. To put this in perspective: At the current gold price of over USD 2,700 per ounce, the profit margin should be over 50%. Production would enable Desert Gold to explore further sections, distribute a dividend, and/or buy back its own shares. So the stock is extremely interesting even without a takeover.

    This is also confirmed by the analysts at GBC Research, who recommend Desert Gold shares as a "Buy" with a target price of USD 0.31. This fair value is based on a gold price of around USD 2,300 – currently over USD 2,700. Desert Gold's shares are currently trading at USD 0.08. For more detailed research and insights, the full report is available here.

    Evotec: Buckle up for November 6

    Evotec presents a more complex situation than Desert Gold for any potential acquirer. After a challenging year, it is still unclear what legacy issues the biotech company has to deal with. The quarterly report could provide clarity. This is scheduled to be published on November 6. Investors and analysts anticipate that the new CEO will provide details on the Company's realignment and present target figures for the coming years. If it becomes clear that the legacy issues have been resolved and that profits will rise again, the stock may become attractive to pharmaceutical and biotech companies again. With a market capitalization of EUR 1.27 billion, Evotec could offer a compelling opportunity despite its size.

    Warburg Research also believes that Evotec will present weak figures on November 6. Although the analysts continue to recommend the stock as a "Buy" with a target price of EUR 14 (the current price is just over EUR 7), a sharp drop in earnings will likely be reported for the third quarter. Sales are expected to decline slightly. In the future, Evotec wants to focus more on profitability, even if this means lower sales growth. So the stock is not a growth story for the time being.

    Nel: Rescue from India?

    Unfortunately, Nel is still far from profitability – despite great efforts and announcements in recent years. The latest quarterly figures have once again been disappointing. The Norwegian company cannot get a grip on its losses and the weak order intake shows that growth is also likely to weaken in the future. Even the spin-off of the subsidiary Cavendish Hydrogen has not provided the hoped-for breakthrough.

    The hope for shareholders lies almost exclusively in a takeover of the former hydrogen high-flyer. After all, there is already a potential buyer. In the first half of 2024, the Norwegians announced a collaboration with India's largest private company, Reliance Industries. The partnership will give Nel access to a rapidly growing market and is intended to meet Reliance's global demand for electrolysers. Since the announcement of the collaboration, takeover rumours have repeatedly arisen, even though it is currently quiet on this front. The fact that no joint project or update on successes in India has been reported does not suggest a quick takeover either.


    Desert Gold is likely the most attractive takeover candidate of the three presented. The upcoming gold production could drive the stock up even if the Company remains independent. With Evotec, investors should exercise patience. The core of the Company is attractive. Once it has freed itself from its legacy issues, the share price should rise. Otherwise, a takeover is likely sooner or later. Should Nel be taken over after all, the operational development does not suggest that a significant premium can be expected. Therefore, Nel does not currently present a compelling buy.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Fabian Lorenz

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author



    Related comments:

    Commented by Stefan Feulner on November 20th, 2026 | 05:55 CET

    Merck KGaA, BioNxt Solutions and Novartis – A billion-dollar market is being reshaped

    • Biotechnology

    Multiple sclerosis has long been a billion-dollar market. But as established drugs come under pressure from expiring patents, new therapeutic approaches are advancing through clinical development. The focus is not just on better active ingredients, but increasingly on easier ways of administering treatments. A German pharmaceutical group is battling generic competition, a small biotech developer is betting on a new drug delivery format, and a Swiss industry giant has reported promising Phase 3 data. This creates significant opportunities for investors, each with a different risk profile.

    Read

    Commented by Carsten Mainitz on November 20th, 2026 | 05:55 CET

    Gold Below USD 4,000! Central Bank Buying at Record Highs! What Matters Now for Kobo Resources, Barrick and Deutsche Börse!

    • Gold
    • Precious metals
    • Explorer
    • Gold producer
    • Xetra-Gold
    • Stock exchange
    • Investments
    • Real assets
    • Interest rates
    • Inflation
    • US dollar
    • Safe-haven currency

    Central banks are massively increasing their gold reserves, yet the price is falling to a 14-month low. The World Gold Council estimates net purchases in the third quarter at 321 tonnes. China's central bank bought 26 tonnes of gold in October alone, the largest monthly purchase in three years. But why is the price of the precious metal falling? The explanation lies in the bond market, among other factors. Signals from the US Federal Reserve make further interest rate rises more likely. The US dollar also strengthened. However, long-term investors should remain calm. Central bank purchases and its role as a safe-haven currency amid spiralling government debt are ultimately the most compelling arguments. Goldman Sachs sees a price target of USD 4,650 by the end of 2027. How should investors position themselves now - explorer, producer or product?

    Read

    Commented by Nico Popp on November 19th, 2026 | 05:25 CET

    Lahontan Gold, Barrick Mining and Newmont: Nevada comes to Wall Street

    • Gold
    • Nevada
    • Production
    • Exploration
    • IPO

    The gold price is falling to its lowest level since October 2025 as investors expect the US Federal Reserve to raise interest rates in December. At the same time, the Monetary Authority of Singapore (MAS) is opening its vault to foreign central banks, with space for up to 500 tonnes of gold. Against this backdrop, Barrick Mining is listing its North American mines as a separate company on the New York Stock Exchange. What does this mean for small developers in Nevada, such as Lahontan Gold, which is seeking to bring a mothballed mine back into production?

    Read